Navigation Links
Tiny mutation triggers drug resistance for patients with one type of leukemia
Date:5/28/2014

A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug. In a correspondence published online May 28 in the New England Journal of Medicine, they show how the mutation triggers resistance. Their finding could guide development of new agents to treat drug-resistant disease.

Ibrutinib received accelerated approval from the Food and Drug Administration for use in chronic lymphocytic leukemia in February. It has revolutionized treatment, transforming CLL from a deadly disease to a chronic one. But about eight percent of patients develop resistance to this lifesaving drug.

In this study, the researchers describe a point mutation in one participant enrolled in a multi-center clinical trial. This patient stopped responding to treatment after almost 20 successful months. The mutation destabilized the binding of ibrutinib to its target, a protein that regulates cell replication, allowing leukemic cells to multiply freely.

"In a way, we are repeating, at a faster pace, the story of Gleevec (imatinib), a landmark drug that transformed care for a different type of leukemia," said study senior author Y. Lynn Wang, MD, PhD, professor of pathology at the University of Chicago. "That story began with development of an effective drug with few side effects, but in many patients the leukemia eventually found a way around it after long-term use. So researchers developed second-line drugs to overcome resistance."

The ibrutinib study began in 2010 at Weill Cornell Medical College in New York City, one of several sites for a phase 1 clinical trial of ibrutinib. The researchers recruited 16 patients with CLL whose disease had progressed or relapsed despite multiple treatments.

Wang, who recently moved from Cornell to the University of Chicago, arranged to track the progres
'/>"/>

Contact: John Easton
john.easton@uchospitals.edu
773-795-5225
University of Chicago Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Ataluren Phase 3 trial results in nonsense mutation cystic fibrosis
2. Study shows breastfeeding, birth control may reduce ovarian cancer risk in women with BRCA mutations
3. Identification of genetic mutations involved in human blood diseases
4. Finnish team of researchers finds a mutation in a tumor of the jaw
5. Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment
6. Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses
7. Study shows preventive ovarian surgery in BRCA1 mutation carriers should be performed early
8. Preventive oophorectomy reduces risk of death by 77 percent for women with BRCA mutation
9. High frequency of EGFR mutations found in Asian population
10. Common blood cancer may be initiated by single mutation in bone cells
11. Multi-institutional team finds targetable mutation in rare brain tumor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... common cause of endophthalmitis, a potentially blinding condition that ... injections, are the well-known staphylococci ("staph") and ... study published in the August issue of Ophthalmology ... of cases at New York Eye and Ear Infirmary ... found that gram-positive bacteria, which include staph and strep ...
(Date:8/20/2014)... The non-small cell lung cancer (NSCLC) market value ... the top 8 developed nations, from just over USD ... billion by 2020-end, posting a CAGR of 6.6% during ... driven by innovative therapies entering the squamous cell carcinoma ... the non-squamous segment. Thus, patients with SCC are expected ...
(Date:8/20/2014)... Caddis Partners LLC, has built one of the ... company in recent years, developing or acquiring 2 million ... including more than $100 million last year alone. , ... new geographic regions and a wider array of product ... announce an enhanced brand identity that includes a new ...
(Date:8/20/2014)... Angeles, CA (PRWEB) August 20, 2014 ... it is bringing on Wrench Advisors as a ... tasks including international large accounts. , As Wrench ... sales consultants can help your organization plan and ... executives and global distribution channels. Our experience developing ...
(Date:8/20/2014)... The award-winning plastic surgery group, The Aesthetic Center ... Houston to a third office, located in Katy, Texas ... ACPS plastic surgeon Dr. Rolando Morales said the expansion ... risen to become one of the largest, most respected ... its establishment in 1996 by plastic surgeons Dr. Christopher ...
Breaking Medicine News(10 mins):Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Biocide Systems Announces Partnership with Wrench Advisors 2Health News:Aesthetic Center for Plastic Surgery Expands Its Reach in Texas 2
... Vision ... Expand Access to Care, WASHINGTON, April 9, 2008 ... health care,policy issues by doctors of optometry from his district ... in West Virginia and the AOA are working to pass ...
... 9 Nu Skin Enterprises,Inc. (NYSE: NUS ) ... the market opening on Thursday, May 1, 2008., ... a,conference call with the investment community later that same ... can expect to hear,management review past results and discuss ...
... housework, is good for mental health , , WEDNESDAY, April 9 (HealthDay ... clean your house and boost your mood. , In ... activity a week helped mental health, although the more vigorous the ... published online Thursday in the British Journal of Sports Medicine ...
... 9 The following statement,was issued today by William ... York,s leaders have taken historic action to protect the ... use by increasing,the state cigarette tax by $1.25 to ... tax increase ever enacted and gives New York the,highest ...
... One month of tough breathing may help asthma sufferers breathe ... University of Houston professor. , In a move ... Hippocratic Oath first do no harm Richard Bond, ... long-standing medical taboo to treat asthma. Although counterintuitive, Bonds ...
... may also identify children at risk , , WEDNESDAY, April ... responsible for cardiac hypertrophy (thickening of the heart muscle) ... this rare but life-threatening condition in children, says a ... children who had no family history of the condition, ...
Cached Medicine News:Health News:Sen. Robert Byrd Receives AOA Health Care Leadership Award 2Health News:Whisk Those Blues Away 2Health News:New York Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 2Health News:First do no harm? UH prof taking opposite approach to treat asthma 2Health News:First do no harm? UH prof taking opposite approach to treat asthma 3Health News:First do no harm? UH prof taking opposite approach to treat asthma 4Health News:Gene Mutations for Rare Heart Disease Also Found in Kids 2
(Date:8/20/2014)... , Aug. 20, 2014  Amerigen Pharmaceuticals Ltd. announces ... Ltd., has received Chinese FDA (CFDA) approval and ... Tablets into the China ... and distribution agreement with Sinochem Jiangsu Pharmaceutical Co., ... US FDA approved and China CFDA certified oral ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: The Market for ... The European, Middle Eastern and African ... devices. As part of its coverage, this study: ... on the EMEA medical device markets and estimates ...
(Date:8/20/2014)... , Aug. 20, 2014 ... research report is available in its catalogue: ... Records http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html ... for electronic medical records (EMR) for nearly a ... report of our findings. Our report has become ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8
... April 25, 2011 The 2010 Pharmacy Today ... American Pharmacists Association , reveals pharmacists believe that ... was recommended by their pharmacist, 92% of pharmacists walk ... a product selection and the average patient consult takes ...
... Scientific Corporation (NYSE: BSX ) today ... and launch of the ION™ Paclitaxel-Eluting Platinum Chromium ... technology.  The ION Stent System incorporates a unique ... stenting and intended to improve the acute performance ...
Cached Medicine Technology:Pharmacists Offer Guidance on Top Over-The-Counter Medications 2Pharmacists Offer Guidance on Top Over-The-Counter Medications 3Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 2Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 3Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 4Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 5
Sedillot periosteal elevator, 16 mm, sharp, 7"....
Periosteal elevator #9H, 17.5 cm, 7"....
Obwegeser periosteal elevator, angled, 9 mm, 20 cm, 8"....
... The Anterior Isola System is ... scoliotic, lordotic or kyphotic spinal ... stiff fixation bridge parallel to ... spine. The system, developed for ...
Medicine Products: